Kenvue appoints Kirk Perry as interim CEO after Thibaut Mongon's exit and launches strategic review to simplify operations.

American consumer health company Kenvue's Board of Directors announced new actions to unlock shareholder value and an interim ...

Board director Kirk Perry has been named interim CEO while the company ... Mongon’s departure follows the appointment of a new chief financial officer in May, when Amit Banati replaced Paul Ruh. In a ...

Kenvue has fired its CEO Thibaut Mongon, the consumer health company said on Monday, in its second major executive shake-up this year amid mounting investor pressure to boost performance. Mongon also ...

Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors is implementing a set of actions to enable the Company to unlock shareholder value and reach its full potential. The Board has made ...

Kenvue KVUE 0.59%, the Johnson & Johnson spinoff that makes Tylenol and Benadryl, said Chief Executive Thibaut Mongon has departed and that the company is considering simplifying its portfolio ...

Kenvue KVUE2.01%increase; green up pointing triangle, the Johnson & Johnson spinoff that makes Tylenol and Benadryl, named director Kirk Perry as interim chief executive officer. The Skillman, N.J ...

Kenvue, which makes powerhouse consumer health brands such as Listerine mouthwash and pain reliever Tylenol, saw its second-quarter sales slip 4%, the company also reported on Monday.

Kenvue appoints Kirk Perry as interim CEO, sees Q2 adjusted EPS of $0.28 to $0.29 Jul. 14, 2025 7:10 AM ET Kenvue Inc. (KVUE) Stock By: Meghavi Singh, SA News Editor 2 Comments Play (2min) ...

Kenvue says that CEO Thibaut Mongon is departing as the maker of Listerine and Band-Aid brands continues with a strategic review of the company. Kenvue used to be a part ...